Marshall Wace
TRIB

Marshall Wace’s Trinity Biotech TRIB Stock Holding History

Marshall Wace’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,941
Closed -$75K – 4282
2021
Q3 		$75K Sell
6,941
-4,170
-38% -$48.9K ﹤0.01% 2916
2021
Q2 		$163K Sell
11,111
-7,025
-39% -$117K ﹤0.01% 2484
2021
Q1 		$341K Buy
+18,136
New +$436K ﹤0.01% 2083

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Marshall Wace's TRIB Position: Q4 2021 in Review

Marshall Wace sold out of Trinity Biotech (TRIB) in Q4 2021, closing a stake of 6,941 shares — an estimated $75K sold.

Marshall Wace first reported a position in TRIB in Q1 2021 and held it in 3 quarters. The position peaked at $341K in Q1 2021. 21 funds tracked by Wall St. Rank hold TRIB as of Q4 2021.

  • Marshall Wace reported no remaining Trinity Biotech position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 6,941 Trinity Biotech shares in Q4 2021, an estimated $75K.
  • Marshall Wace first reported a position in Trinity Biotech in Q1 2021 and held it in 3 quarters.
  • Marshall Wace's Trinity Biotech position peaked at $341K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.